Retirement Systems of Alabama Boosts Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Retirement Systems of Alabama grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 476.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 131,382 shares of the biopharmaceutical company's stock after acquiring an additional 108,589 shares during the period. Retirement Systems of Alabama owned 0.12% of Regeneron Pharmaceuticals worth $83,326,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the business. Pinney & Scofield Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter worth $25,000. Rakuten Securities Inc. raised its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the period. OFI Invest Asset Management purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $28,000. Avalon Trust Co bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $36,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Down 0.8%

Shares of NASDAQ REGN traded down $3.86 during midday trading on Friday, hitting $509.72. The company's stock had a trading volume of 2,259,294 shares, compared to its average volume of 891,435. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,211.20. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The firm has a market cap of $55.03 billion, a P/E ratio of 12.98, a price-to-earnings-growth ratio of 1.88 and a beta of 0.31. The business's 50 day moving average is $558.34 and its two-hundred day moving average is $641.68.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $9.55 earnings per share. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were given a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on REGN. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Canaccord Genuity Group upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, April 22nd. Bank of America cut their price target on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating for the company in a research note on Thursday, April 17th. JPMorgan Chase & Co. dropped their price objective on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a research note on Monday, June 9th. Finally, UBS Group decreased their target price on Regeneron Pharmaceuticals from $633.00 to $560.00 and set a "neutral" rating on the stock in a research note on Thursday, June 5th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $836.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.